Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 447 of 1,261
  1. US 10537594

    Targeted transplantation of mitochondria to hepatocytes

    UNIVERSITY OF CONNECTICUT · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  2. US 10538570

    Targeted and modular exosome loading system

    Northwestern University · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  3. US 10537535

    Histone deacetylase inhibitors

    The Regents of the University of California · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  4. US 10537595

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  5. US 10538513

    Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  6. US 10538749

    Mutant OPAA enzymes with increased catalytic efficiency on cyclosarin

    The United States of America as represented by the Secretary of the Army · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  7. US 10538579

    Bispecific pertussis antibodies

    The Board of Regents of the University of Texas System · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  8. US 10538787

    Compositions for linking DNA-binding domains and cleavage domains

    Sangamo Therapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  9. US 10538765

    Organic compositions to treat EPAS1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  10. US 10538762

    Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat

    The Board of Regents of the University of Texas System · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  11. US 10538532

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  12. US 10537645

    Protein-polymer-drug conjugates

    Mersana Therapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  13. US 10538530

    Vasopressin receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  14. US 10537642

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  15. US 10537635

    Detection of arginine methylation of EGFR for prediction of resistance to therapy

    The Board of Regents of the University of Texas System · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  16. US 10537611

    Methods of treating lung cancer

    Five Prime Therapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  17. US 10537596

    Bone marrow adipose portion isolation device and methods

    Regenexx, LLC · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  18. US 10537581

    Vaginal inserted estradiol pharmaceutical compositions and methods

    Compass Therapeutics LLC · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  19. US 10537577

    Compounds and compositions for ossification and methods related thereto

    United States Government as represented by the Department of Veterans Affairs · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  20. US 10537565

    Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

    Vertex Pharmaceuticals Incorporated · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  21. US 10537560

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  22. US 10537553

    Methods of treating muscular dystrophy

    BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  23. US 10537537

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  24. US 10537529

    Cell-free methods of producing vault particles and vault particles resulting therefrom

    The Regents of the University of California · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.